In observance of National Women and Girls HIV/AIDS Awareness Day on March 10, 2007, Vivian Berryhill, president of the National Coalition of Pastors’ Spouses, issued the following statement urging women of all ages to be routinely tested for HIV:
The decade-long research that University of Nevada, Reno College of Science Chemistry Professor Thomas Bell has invested in the development of an extremely effective HIV/AIDS-fighting compound received an important boost recently when one of Bell’s articles made the list of the 100 most influential publications in the HIV/AIDS research field for 2006.
An assistant professor of dental hygiene at New York City College of Technology (City Tech), she is on a mission to educate her students and a variety of providers in the metropolitan New York area — hygienists, physicians, physician assistants, nurse practitioners and hospital HIV/AIDS counselors — to routinely conduct periodontal evaluations and oral cancer and vital sign screenings as well as how to recognize the clinical signs of such systemic diseases as HIV/AIDS.
On International Women’s Day, the UK National AIDS Trust calls for further support for the development of microbicides and vaccines, new prevention technologies that could prevent millions of women from becoming infected with HIV.
Statement of Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, on National Women and Girls HIV/AIDS Awareness Day, March 10, 2007 :
Researchers at the University of Arizona College of Medicine?s Department of Immunobiology have discovered that the agent that causes tuberculosis (TB), Mycobacterium tuberculosis, produces a new type of virulence factor called Mycobacterium Tuberculosis Pili (MTP). Their findings suggest that MTP could be a promising, new TB-vaccine candidate. Worldwide, three million people die each year from tuberculosis and an estimated 1.2 billion are infected with the bacteria.
New evidence suggests that the risk of HIV transmission may be highest in the early stages of infection. According to a study published in the April 1 issue of the Journal of Infectious Diseases, now available online, early infection accounted for nearly half of all transmission occurrences in an HIV-infected population in the province of Quebec, Canada.
Devastating blood-borne fungal infections that can be lethal for HIV/AIDS, cancer and organ transplant patients may be treated more successfully, thanks to a new drug delivery method developed by researchers at the University of British Columbia in Vancouver.
The Global Fund to Fight AIDS, Tuberculosis and Malaria enthusiastically welcomes Japan?s announcement of a new contribution of US$186 million.
At this week’s major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an entirely new way. A 24 week analysis showed that approximately twice as many patients receiving maraviroc with an optimized background regimen achieved undetectable virus in the blood than if an optimized regimen was given alone.